Liminatus Pharma, Inc. (LIMNW) stock
Close on Oct 30, 2026Market cap $189.39MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $189.39M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 630.02
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$12.52M
- EPS, diluted
- -$0.43
- Free cash flow
- -$9.98M
- Book value per share
- $0.01
- Diluted shares
- 48M
Trading
- Previous close
- $0.04
- Open
- $0.04
- Day's range
- $0.04 – $0.04
- Average volume (20 days)
- 721
- Beta (5 years)
- 0.72
- 52-week range
- $2.75 – $141.50
- RSI (14 days)
- 34.4
- Volatility (1 year)
- 177.7%
- Relative volume
- 0.03×
- WACC
- 8.6%
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 30, 2026. The S&P 500 is measured by the SPY fund.
| Period | LIMNW | S&P 500 | Difference | LIMNW per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -27.9% | -0.9% | −27.0 pts | ||
| 3 months | -2.7% | +2.1% | −4.8 pts | ||
| Year to date | +14.3% | +11.7% | +2.6 pts | ||
| 1 year | -68.8% | +12.4% | −81.1 pts | ||
| 3 years | +59.4% | +88.6% | −29.2 pts | +16.8% | +23.5% |
| 5 years | -95.9% | +75.9% | −171.8 pts | -47.1% | +12.0% |
Three years at a glance
Fiscal years 2023 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Liminatus Pharma filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- News
- News
- Update
- Update
About Liminatus Pharma
Biological Products, (No Diagnostic Substances)
Liminatus Pharma, Inc. is a preclinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies. Its principal product candidate is IBA101, a next-generation humanized anti-CD47 monoclonal antibody designed to act as an immune checkpoint inhibitor. The therapy works by blocking the CD47 signal that allows malignant cells to evade immune detection, thereby promoting tumor uptake by macrophages while avoiding the destruction of red blood cells and platelets. The company intends to direct its initial treatments toward patients diagnosed with advanced solid tumors, including non-small cell lung cancer.
Company profile, executives and historyLiminatus Pharma stock: common questions
What is Liminatus Pharma's stock price?
LIMNW closed at $0.04 on Oct 30, 2026, up 0.00% on the day. Over the past 52 weeks it traded between $2.75 and $141.50.
What is Liminatus Pharma's market cap?
Liminatus Pharma was worth $189.39M at the close on Oct 30, 2026: the share price times the diluted shares outstanding.
What is LIMNW's P/E ratio?
Liminatus Pharma lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.43), so it has no meaningful P/E ratio.
Does Liminatus Pharma pay a dividend?
No. Liminatus Pharma has not paid a cash dividend over the last twelve months.
How has LIMNW stock performed over the past year?
Including dividends, LIMNW returned -68.8% over the past year, against +12.4% for the S&P 500.
Who are Liminatus Pharma's competitors?
Companies most similar to Liminatus Pharma by business, industry and size include CPMV, CMPX, CERO, IPHA, CGON.